Compare PBH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBH | PHVS |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2004 | 2020 |
| Metric | PBH | PHVS |
|---|---|---|
| Price | $50.24 | $38.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $75.33 | $41.82 |
| AVG Volume (30 Days) | 406.7K | ★ 860.5K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $975,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | $81.62 | ★ N/A |
| Revenue Growth | ★ 36.77 | N/A |
| 52 Week Low | $42.62 | $20.65 |
| 52 Week High | $71.07 | $43.25 |
| Indicator | PBH | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 63.05 |
| Support Level | $49.73 | $24.73 |
| Resistance Level | $51.57 | N/A |
| Average True Range (ATR) | 1.34 | 1.76 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 6.11 | 47.88 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.